Safety assessment of peroxide antimalarials: Clinical and chemical perspectives

British Journal of Clinical Pharmacology

Volumn 46, Issue 6, 1998, Pages 521-529

  Kevin Park, B ^a   O'Neill, Paul M ^a   Maggs, James L ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEETHER; ARTEFLENE; ARTEMETHER; ARTEMISININ; CHLOROQUINE; FENOZAN; TETROXANE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ARTICLE; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; FEVER; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALARIA; NAUSEA; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RASH; RISK ASSESSMENT; SEIZURE; TERATOGENICITY; TOXICITY TESTING;

ANIMALS; ANTIMALARIALS; ARTEMISININS; BIOTRANSFORMATION; FERRIC COMPOUNDS; HUMANS; MALARIA; PEROXIDES; SESQUITERPENES; TREATMENT OUTCOME;

EID: 0031722604     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00838.x     Document Type: Article

References (63)

1. Meshnick SR, Taylor TE, Kamchomvongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 1996; 60: 301-315.
2. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341: 603-608.
3. Titulaer HAG, Zuidema J, Kager PA, Wetsteyn JCFM, Lügt CB, Merlus FWHM. The pharmacokinetics of artemisinin after oral, intramuscular and rectal administration to volunteers. J Pharm Phannacol 1990; 42: 810-813.
4. Batty KT, Thu LTA, Davis TME, et al A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. BrJ Clin Phannacol 1998; 45: 123-129.
5. Teja-Isavadharm P, Nosten F, Kyle DE, et al. Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy-subjects-use of simultaneous measurement by highperformance liquid-chromatography and bioassay. BrJ Clin Phannacol 1996; 42: 599-604.
6. Hofheinz W, Burgin H, Gocke E, et al. Ro 42-1611 (arteflene), a new effective antimalarial: chemical structure and biological activity. Trop Med Parasitai 1994; 45: 261-265.
7. Meshnick SR, Jefford CW, Posner GH, Avery MA, Peters W. Second-generation antimalarial endoperoxides. Parasitai Today 1996; 12: 79-82.
8. de Vries PJ, Dien TK. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs 1996; 52: 818-836.
9. Jeffbrd CW, Velarde JA, Bernardelli G, Bray DH, Warhurst DC, Milhous WK. Synthesis, structure and antimalarial activity of tricyclic 1,2,4-trioxanes related to artemisinin. Helv Chim Acta 1993; 76: 2775-2778.
10. Vennerstrom JL, Fu HN, Ellis WY, et al. Dispiro-l,2,4,5-tetraoxanes-a new class of antimalarial peroxides. J Med Chem 1992; 35: 3023-3027.
11. Posner GH, Oh CH, Webster HK, Ager AL, Rossan RN. New, antimalarial, tricyclic 1,2,4-trioxanes-evaluations in mice and monkeys. Am J Trop Med Hyg 1994; 50: 522-526.
12. Grigorov M, Weber J, Tronchet MJ, Jefford CW, Milhous WK, Marie D. A QSAR study of the antimalarial activity of some synthetic 1,2,4-trioxanes. J Client InfCompiit Sei 1997; 37: 124-130.
13. Sy ND, Hoan DB, Dung NP, et al. Treatment of malaria in Vietnam with oral artemisinin. Am J Trop Med Hyg 1993; 48: 398-402.
14. Qinghaosu Antimalarial Coordinating Research Group. Antimalarial studies on qinghaosu. Chin MedJ 1979; 92: 811-816.
15. Price RN, Nosten F, Luxemburger C, et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet 1996; 347: 1654-1658.
16. White NJ. Artemisinin: current status. Tram R Soc Trop Med Hyg 1994; 88: S3-S4.
17. Hassan-Ali M, Bjorkman A, Ashton M. In vitro activity of artemisinin, its derivatives, and pyronaridine against different strains of Plasmodium falciparum. Trans R Soc Trop Med Hyg 1990; 84: 635-637.
18. Ashton M, Hai TN, Sy ND, et al. Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. Dnig Metab Dispos 1998; 26: 2601-2605.
19. RadloffPD, Philipps J, Nkeyi M, Sturchler D, Mittelholzer ML, Kremsner PG. Arteflene compared with mefloquine for treating Plasmodium facliparum malaria in children. Am J Trop Med Hyg 1996; 55: 259-262.
20. Barradell LB, Fitton A. Artesunate: A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Dmgs 1995; 50: 714-741.
21. Thomas SHL. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Dnig React Toxicol Rev 1994; 13: 77-102.
22. Hien TT, Day NPJ, Phu NH, et al. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum-malaria. N EnglJ Med 1996; 335: 76-83.
23. Von Seidlein L, Jaffar S, Greenwood B. Prolongation of the QTc interval in African children treated for falciparum malaria. Am J Trop Med Hyg 1997; 56: 494-497.
24. Vanhensbroek MB, Onyiorah E, Jaffar S, et al. A trial of artemether or quinine in children with cerebral malaria. N EnglJ Med 1996; 335: 69-75.
25. Huffman SL. Artemether in severe malaria-still too many deaths. N EnglJ Med 1996; 335: 124-126.
26. Miller LG, Panosian CB. Ataxia and slurred speech after artesunate treatment for falciparum malaria. N EnglJ Med 1997; 336: 1328.
27. Davis TME, Edwards GO, McCarthy JS. Artesunate and cerebellar dysfunction in falciparum malaria. N EnglJ Med 1997; 337: 792.
28. Gachot B, Eliaszewicz M, Dupont B. Artesunate and cerebellar dysfunction in falciparum malaria. N EnglJ Med 1997; 337: 792-793.
29. Miller LG, Panosian CD. Artesunate and cerebellar dysfunction in falciparum malaria-reply. N EnglJ Med 1997; 337: 793.
30. Phillips-Howard PA, Wood D. The safety of antimalarial drugs in pregnancy. Drug Saf\996; 14: 131-145.
31. World Health Organization (1994). The role of artemisinin and its derivatives in the current treatment of malaria (1994-95).
32. Chi HT, Ramu K, Baker JK, et al. Identification of the m vivo metabolites of the antimalarial arteether by thermospray high-performance liquid chromatography/mass spectrometry. Biol Mass Spcctrom 1991; 20: 609-628.
33. Maggs JL, Madden S, Bishop LP, O'Neill PM, Park BK. The rat biliary metabolites of dihydroartemisinin, an antimalarial endoperoxide. Drug Metab Dispos 1997; 25: 1200-1204.
34. Ramu K, Baker JK. Synthesis, characterization, and antimalarial activity of the glucuronides of the hydroxylated metabolites of arteether. J Med Chem 1995; 38: 1911-1921.
35. Asawamahasakda W, Ittarat I, Pu YM, Ziffer H, Meshnick SR. Reaction of antimalarial endoperoxides with specific parasite proteins. Atitiinicrob Agents Chemother 1994; 38: 1854-1858.
36. Gumming JN, Ploypradith P, Posner GH. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism (s) of action. AAv Phannacol 1996; 37: 253-297.
37. Krungkrai SR, Yuthavong Y. The antimalarial action on Plasmodium falciparum of quinghaosu and artesunate in combination with agents that modulate oxidative stress. Trans R Soc Trop Med Hyg 1987; 81: 710-714.
38. Meshnick SR, Yang YZ, Lima V, Kuypers F, Kamchonwongpaisan S, Yuthavong Y. Iron-dependent free radical generation and the antimalarial artemisinin (qinghaosu). Antimicrob Agents Chemother 1993; 37: 1108-1114.
39. Brewer TG, Grate SJ, Peggins JO, et al. Fatal neurotoxicity of arteether and artemether. AmJ Trop Med Hyg 1994; 51: 251-259.
40. Kamchonwongpaisan S, McKeever P, Hossler P, Ziffer H, Meshnick SR. Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro. AmJ Trop Med Hyg 1997; 56: 7-12.
41. Petras JM, Kyle DE, Gettayacamin M, et al. Arteether: Risks of two-week administration in Macaca mulatto. AmJ Trop Med Hyg 1997; 56: 390-396.
42. Davis TME, Breheny FX, Kendall PA, et al. Severe falciparum malaria with hyperparasitaemia treated with intravenous artesunate. Med J Austral 1997; 166: 416-418.
43. Wesche DL, Da Coster MA, Tortella FC, Brewer TG. Neurotoxicity of artemisinin analogs m vitro. Antimicrob Agents Cliemother 1994; 38: 1813-1819.
44. Fishwick J, McLean WG, Edwards G, Ward SA. The toxicity of artemisinin and related compounds on neuronal and glial cells in culture. C/ieui Biol Interact 1995; 96: 263-271.
45. Smith SL, Fishwick J, McLean WG, Edwards G, Ward SA. Enhanced in vitro neurotoxicity of artemisinin derivatives in the presence of haemin. Biochem Phannacol 1997; 53: 5-10.
46. Yang Q-C. The antimalarial and toxic effects of artesunate on animal models. J Trad Chin Med 1982; 22: 99-103.
47. China Co-operative Group on Qinghaosu and its derivatives as antimalarials. Chemical studies on qinghaosu (artemisinin). J Trad Chin Med 1982; 2: 3-8.
48. Smith SL, Maggs JL, Edwards G, Ward SA, Park BK, McLean WG. The role of iron in neurotoxicity-a study of novel antimalarial drugs. Naiwtoxicol 1998; in press:.
49. Duettner GR. The reaction of Superoxide, formate radical, and hydrated electron with transferrin and its modelcompound, Fe(III)-ethylenediamine- N,N'bis[2-(2-hydroxyphenyl) acetic acid] as studied by pulseradiolysis. J Biol Chem 1987; 262: 11995-11998.
50. Haber F, Weiss J. The catalytic decomposition of hydrogen peroxide by iron salt. Proc R Soc A Math Phys Sei 1934; 147: 332-351.
51. Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of iron salt is a feasible source of hydroxyl radicals m vivo. BiochemJ 1982; 205: 461-462.
52. Posner GH, Park SB, Gonzalez L, et al. Evidence for thé importance of high valent Fe = O and of a diketone in the molecular mechanism of action of antimalarial trioxane analogs of artemisinin. J Am Chem Soc 1996; 118: 3537-3538.
53. O'Ncill PM, Bishop LP, Searle NL, et al. The biomimetic iron-mediated degradation of arteflene (Ro-42-1611), an endoperoxide antimalarial: implications for the mechanism of antimalarial activity. Tetrahedron Lett 1997; 38: 4263-4266.
54. Baker JK, Yarber RH, Hufford CD, Lee IS, Elsohly HN, McChesney JD. Thermospray mass-spectroscopy high-performance liquid-chromatographic identification of the metabolites formed from arteether using a rat-liver microsome preparation. Biomed Environ Mass Spectrom 1989; 18: 337-351.
55. Ullrich V, Brugger R. Prostacyclin and thromboxane synthase-new aspects of hemethiolate catalysis. Ange Chem lut Ed Engl 1994; 33: 1911-1919.
56. White NJ. Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans R Soc Trop Med Hyg 1994; 88: S41-S43.
57. Thomas CG, Ward SA, Edwards G. Selective determination, in plasma, of artemether and its major metabolite, dihydroartemisinin, by high-performance liquid chromatography with ultraviolet detection. J Cliromatogr 1992; 583: 131-136.
58. Burgess JR, Yang H, Chang M, Rao MK, Tu CP, Reddy CC. Enzymatic transformation of PGH2 to PGF2-aIpha catalysed by glutathione transferases. Biochem Biophys Res Commun 1987; 142: 441-447.
59. Gutteridge JMC. Metalloproteins as donors of metal ions for oxygen chemistry. In Oxidative Damage and Repair, ed Davies KJA, Oxford: Pergamon Press, 1990: 355-363.
60. Ponka P, Beaumont C, Richardson DR. Function and regulation of transferrin and ferritin. Semin Hematol 1998; 35: 35-54.
61. Yoshida T, Tanaka M, Sotomatsu A, Hira S. Activated microlgia cause superoxide-mediated release of iron from ferritin. Neiiroscience Lett 1995; 190: 21-24.
62. Koeppen AH, Dickson AC, McEvoy JA. The heterogeneous distribution of brain transferrin. J Nenropathol Exp Neural 1995; 54: 395-403.
63. Connor JR, Pavlick G, Karli D, Menzies SL, Palmer C. A histochemical study of iron-positive cells in the developing rat brain._/ Comp Neural 1995; 355: 111-123.